WEST

Generate Collection | Print

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: WO 200156608 A1, US 2001033844 A1, AU 200136636 A

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

Generate Collection | Print

Terms	Documents
animune	1

Display Format: [ ] Change Format

Previous Page Next Page

WEST

End of Result Set

☐ Generate Collection Print

L7: Entry 1 of 1 File: DWPI Aug 9, 2001

DERWENT-ACC-NO: 2001-465701
DERWENT-WEEK: 200150

TITLE: A transfer factor (I) effective to confer cell-mediated immunity to Human Herpesvirus-6A (HHV-6A) and Human Herpesvirus-6B and for treating chronic fatigue syndrome and multiple sclerosis

INVENTOR: SHULER, R R; WILSON, G B ; BREWER, J H

PRIORITY-DATA: 2000US-179647P (February 2, 2000), 2001US-0776010 (February 2, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200156608 A1	August 9, 2001	E	024	A61K045/05
US 2001033844 A1	October 25, 2001		000	A61K039/245
AU 200136636 A	August 14, 2001		000	A61K039/245

INT-CL (IPC): A61 K 39/00; A61 K 39/245; A61 K 45/05; C12 Q 1/70

ABSTRACTED-PUB-NO: US2001033844A
BASIC-ABSTRACT:

NOVELTY - A transfer factor (I) effective to confer cell-mediated immunity where the immune response is to Human Herpesvirus-6A (HHV-6A) and Human Herpesvirus-6B (HHV-6B), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) Producing (M1) (I) comprising immunizing a lactating animal with HHV-6A and HHV-6B, recovering the colostrum from the animal and preparing (I) from the colostrum or immunizing an animal with HHV-6A and HHV-6B, recovering the immune system component from the animal and preparing (I) from the component;

(2) Producing (M2) a composition comprising producing (I) and admixing a carrier.

ACTIVITY - Immunostimulant; neuroprotective; antiviral; analeptic.

MECHANISM OF ACTION - Cell-mediated-immunity-stimulator; vaccine.

Colostrum samples from bovines immunized with HHV-6A and HHV-6B antigens were used as the source for preparation of TF (I). The TF was administered orally. A placebo controlled double blind experiment was performed consisting of 2 patient groups. Group I (HHV-6 TF group) consisted of chronic fatigue syndrome and multiple sclerosis patients who received capsules containing the HHV-6A and HHV-6B TF. Group II (Placebo TF Group) consisted of patients who received control TF preparation. Both groups were evaluated over a period of four months. All patients received 2 capsules three times a day during day 1 to 5, day 31 to 35, and day 61 to 65 of the study. 5 of 8 chronic fatigue syndrome patients who received the HHV-6 TF had a 50% greater reduction in their score and 5 of 8 showed an increase of 50% or greater in their NK cells. Zero controls showed a decrease in symptoms by 50% or an increase in NK cell function by

50%.

USE - (I) is useful for treating chronic fatigue syndrome, multiple sclerosis, an abnormality alleviated by enhancing a subjects immune response to HHV-6A and/or HHV-6B (all claimed).

ABSTRACTED-PUB-NO:

WO 200156608A
EQUIVALENT-ABSTRACTS:

NOVELTY - A transfer factor (I) effective to confer cell-mediated immunity where the immune response is to Human Herpesvirus-6A (HHV-6A) and Human Herpesvirus-6B (HHV-6B), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) Producing (M1) (I) comprising immunizing a lactating animal with HHV-6A and HHV-6B, recovering the colostrum from the animal and preparing (I) from the colostrum or immunizing an animal with HHV-6A and HHV-6B, recovering the immune system component from the animal and preparing (I) from the component;

(2) Producing (M2) a composition comprising producing (I) and admixing a carrier.

ACTIVITY - Immunostimulant; neuroprotective; antiviral; analeptic.

MECHANISM OF ACTION - Cell-mediated-immunity-stimulator; vaccine.

Colostrum samples from bovines immunized with HHV-6A and HHV-6B antigens were used as the source for preparation of TF (I). The TF was administered orally. A placebo controlled double blind experiment was performed consisting of 2 patient groups. Group I (HHV-6 TF group) consisted of chronic fatigue syndrome and multiple sclerosis patients who received capsules containing the HHV-6A and HHV-6B TF. Group II (Placebo TF Group) consisted of patients who received control TF preparation. Both groups were evaluated over a period of four months. All patients received 2 capsules three times a day during day 1 to 5, day 31 to 35, and day 61 to 65 of the study. 5 of 8 chronic fatigue syndrome patients who received the HHV-6 TF had a 50% greater reduction in their score and 5 of 8 showed an increase of 50% or greater in their NK cells. Zero controls showed a decrease in symptoms by 50% or an increase in NK cell function by 50%.

USE - (I) is useful for treating chronic fatigue syndrome, multiple sclerosis, an abnormality alleviated by enhancing a subjects immune response to HHV-6A and/or HHV-6B (all claimed).

ABSTRACTED-PUB-NO: US2001033844A
EQUIVALENT-ABSTRACTS: NOVELTY - A transfer factor (I) effective to confer cell-mediated immunity where the immune response is to Human Herpesvirus-6A (HHV-6A) and Human Herpesvirus-6B (HHV-6B), is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) Producing (M1) (I) comprising immunizing a lactating animal with HHV-6A and HHV-6B, recovering the colostrum from the animal and preparing (I) from the colostrum or immunizing an animal with HHV-6A and HHV-6B, recovering the immune system component from the animal and preparing (I) from the component; (2) Producing (M2) a composition comprising producing (I) and admixing a carrier. ACTIVITY - Immunostimulant; neuroprotective; antiviral; analeptic. MECHANISM OF ACTION - Cell-mediated-immunity-stimulator; vaccine. Colostrum samples from bovines immunized with HHV-6A and HHV-6B antigens were used as the source for preparation of TF (I). The TF was administered orally. A placebo controlled double blind experiment was performed consisting of 2 patient groups. Group I (HHV-6 TF group) consisted of chronic fatigue syndrome and multiple sclerosis patients who received capsules containing the HHV-6A and HHV-6B TF. Group II (Placebo TF Group) consisted of patients who received control TF preparation. Both groups were evaluated over a period of four months. All patients received 2 capsules three times a day during day 1 to 5, day 31

to 35, and day 61 to 65 of the study. 5 of 8 chronic fatigue syndrome patients who received the HHV-6 TF had a 50% greater reduction in their score and 5 of 8 showed an increase of 50% or greater in their NK cells. Zero controls showed a decrease in symptoms by 50% or an increase in NK cell function by 50%. USE - (I) is useful for treating chronic fatigue syndrome, multiple sclerosis, an abnormality alleviated by enhancing a subjects immune response to HHV-6A and/or HHV-6B (all claimed). WO 200156608A

CHOSEN-DRAWING: Dwg.0/0

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:33:36 ON 26 APR 2002

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 08:33:45 ON 26 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 26 Apr 2002  VOL 136 ISS 17
FILE LAST UPDATED: 24 Apr 2002  (20020424/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=> file caplus biosis
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.40       0.61

FILE 'CAPLUS' ENTERED AT 08:33:55 ON 26 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:33:55 ON 26 APR 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> "transfer factor"
L1         3880 "TRANSFER FACTOR"

=> "herpesvirus-6A"
L2           39 "HERPESVIRUS-6A"

=> L1 and L2
L3            1 L1 AND L2

=> "multiple sclerosis"
L4        28612 "MULTIPLE SCLEROSIS"

=> L4 and L1
L5           29 L4 AND L1
```

```
=> herpesvirus and L5
L6            1 HERPESVIRUS AND L5

=> "chronic fatigue" and L1
L7           12 "CHRONIC FATIGUE" AND L1

=> herpesvirus and L7
L8            3 HERPESVIRUS AND L7

=> D L8 IBIB TI SO AU ABS 1-3

L8   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         2001:581739  CAPLUS
DOCUMENT NUMBER:          135:136432
TITLE:                    Human herpes virus 6A and 6B transfer
                          factors for the treatment of chronic
                          fatigue syndrome and multiple sclerosis
INVENTOR(S):              Wilson, Gregory B.; Brewer, Joseph H.
PATENT ASSIGNEE(S):       Animune Inc., USA
SOURCE:                   PCT Int. Appl., 24 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     WO 2001056608      A1   20010809      WO 2001-US3511   20010202
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2001033844      A1   20011025      US 2001-776010   20010202
PRIORITY APPLN. INFO.:                    US 2000-179647P  P  20000202
TI   Human herpes virus 6A and 6B transfer factors for the
     treatment of chronic fatigue syndrome and multiple
     sclerosis
SO   PCT Int. Appl., 24 pp.
     CODEN: PIXXD2
IN   Wilson, Gregory B.; Brewer, Joseph H.
AB   The present invention provides transfer factors that
     confer cell-mediated immunity to Human Herpesvirus-6A and Human
     Herpesvirus-6B.  The invention also provides pharmaceutical
     compns. comprising the transfer factors and methods of
     treating abnormalities in a subject using the transfer
     factors.
REFERENCE COUNT:          6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L8   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         1997:42178  CAPLUS
DOCUMENT NUMBER:          126:102987
```

TITLE: Lessons from a pilot study of **transfer factor** in **chronic fatigue** syndrome

AUTHOR(S): De Vinci, Caterina; Levine, Paul H.; Pizza, Giancarlo; Fudenberg, Hugh H.; Orens, Perry; Pearson, Gary; Viza, Dimitri

CORPORATE SOURCE: Immunoldiagnosis Immunotherapy Unit, 1st Div. Urology Sant'Orsola-Malpighi Hosp., Bologna, Italy

SOURCE: Biotherapy (Dordrecht, Neth.) (1996), 9(1/3, Biological Response Modifiers in Research and Treatment of Cancer, Infectious Diseases, and Immunological and Inflammatory Disorders), 87-90
CODEN: BTHREW; ISSN: 0921-299X

PUBLISHER: Kluwer

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Lessons from a pilot study of **transfer factor** in **chronic fatigue** syndrome

SO Biotherapy (Dordrecht, Neth.) (1996), 9(1/3, Biological Response Modifiers in Research and Treatment of Cancer, Infectious Diseases, and Immunological and Inflammatory Disorders), 87-90
CODEN: BTHREW; ISSN: 0921-299X

AU De Vinci, Caterina; Levine, Paul H.; Pizza, Giancarlo; Fudenberg, Hugh H.; Orens, Perry; Pearson, Gary; Viza, Dimitri

AB **Transfer Factor** (TF) was used in a placebo controlled pilot study of 20 patients with **chronic fatigue** syndrome (CFS). Efficacy of the treatment was evaluated by clin. monitoring and testing for antibodies to Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6). Of the 20 patients in the placebo-controlled trial, improvement was obsd. in 12 patients, generally within 3-6 wk of beginning treatment. Herpes virus serol. seldom correlated with clin. response. This study provided experience with oral TF, useful in designing a larger placebo-controlled clin. trial.

L8 ANSWER 3 OF 3 CAPLUS

ACCESSION NUMBER: 1997:42172 CAPLUS

DOCUMENT NUMBER: 126:88153

TITLE: Use of anti HHV-6 **transfer factor** for the treatment of two patients with **chronic fatigue** syndrome (CFS). Two case reports

AUTHOR(S): Ablashi, Dharam V.; Levine, Paul H.; De Vinci, Caterina; Whitman, James E., Jr.; Pizza, Giancarlo; Viza, Dimitri

CORPORATE SOURCE: Advanced Biotechnologies Inc., Columbia, MD, 21046, USA

SOURCE: Biotherapy (Dordrecht, Neth.) (1996), 9(1/3, Biological Response Modifiers in Research and Treatment of Cancer, Infectious Diseases, and Immunological and Inflammatory Disorders), 81-86
CODEN: BTHREW; ISSN: 0921-299X

PUBLISHER: Kluwer

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Use of anti HHV-6 **transfer factor** for the treatment of two patients with **chronic fatigue** syndrome (CFS). Two case reports

SO Biotherapy (Dordrecht, Neth.) (1996), 9(1/3, Biological Response Modifiers in Research and Treatment of Cancer, Infectious Diseases, and Immunological and Inflammatory Disorders), 81-86
CODEN: BTHREW; ISSN: 0921-299X
AU Ablashi, Dharam V.; Levine, Paul H.; De Vinci, Caterina; Whitman, James E., Jr.; Pizza, Giancarlo; Viza, Dimitri
AB Specific human herpes virus-6 (HHV-6) **transfer factor** (PF) prepn., administered to 2 **chronic fatigue** syndrome patients, inhibited the HHV-6 infection. Prior to treatment, both patients exhibited an activated HHV-6 infection. TF treatment improved the clin. manifestations of CFS in one patient who resumed normal duties within weeks, whereas no clin. improvement was obsd. in the second patient. Thus, HHV-6 specific TF may be of value in controlling HHV-6 infection and related illnesses.

=> D L3 TI SO AU ABS

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
TI Human herpes virus 6A and 6B **transfer factors** for the treatment of chronic fatigue syndrome and multiple sclerosis
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
IN Wilson, Gregory B.; Brewer, Joseph H.
AB The present invention provides **transfer factors** that confer cell-mediated immunity to Human **Herpesvirus-6A** and Human Herpesvirus-6B. The invention also provides pharmaceutical compns. comprising the **transfer factors** and methods of treating abnormalities in a subject using the **transfer factors**.

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 08:39:10 ON 26 APR 2002

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
herpesvirus and transfer adj factor	0

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L16

Refine Search

Recall Text | Clear

Search History

DATE: Friday, April 26, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L16	herpesvirus and transfer adj factor	0	L16
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=AND			
L15	L14 and L8	0	L15
L14	herpesvirus	3151	L14
L13	L8 and perpesvirus	0	L13
L12	L11	0	L12
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L11	herpesvirus and L8	0	L11
L10	HHV-6A and L8	0	L10
L9	HHV-6 and L8	0	L9
L8	transfer adj factor	479	L8
L7	animune	1	L7
L6	animune inc.	0	L6
L5	Brewer J.in.	0	L5
L4	Brewer JH.in.	0	L4
L3	L2 and transfer adj factor	2	L3
L2	Wilson G.in.	168	L2
L1	Wilson GB.in.	0	L1

END OF SEARCH HISTORY

NCBI PubMed National Library of Medicine NLM

PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM Books

Search PubMed for Wilson GB transfer factor Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Sort Save Text Clip Add Order

Show: 20 Items 1-18 of 18 One page.

Entrez PubMed

PubMed Services

Related Resources

1: Wilson GB, Poindexter C, Fort JD, Ludden KD. Related Articles

De novo initiation of specific cell-mediated immune responsiveness in chickens by transfer factor (specific immunity inducer) obtained from bovine colostrum and milk.
Acta Virol. 1988 Jan;32(1):6-18.
PMID: 2897772 [PubMed - indexed for MEDLINE]

2: Vasily DB, Miller OF, Fudenberg HH, Goust JM, Wilson GB. Related Articles

Epidermodysplasia verruciformis: response to therapy with dialyzable leukocyte extract (transfer factor) derived from household contacts.
J Clin Lab Immunol. 1984 May;14(1):49-57.
PMID: 6086930 [PubMed - indexed for MEDLINE]

3: Wilson GB, Fudenberg HH, Keller RH. Related Articles

Guidelines for immunotherapy of antigen-specific defects with transfer factor.
J Clin Lab Immunol. 1984 Feb;13(2):51-8.
PMID: 6202873 [PubMed - indexed for MEDLINE]

4: Wilson GB, Metcalf JF, Fudenberg HH. Related Articles

Treatment of Mycobacterium fortuitum pulmonary infection with "transfer factor" (TF): new methodology for evaluating TF potency and predicting clinical response.
Clin Immunol Immunopathol. 1982 May;23(2):478-91. No abstract available.
PMID: 7049471 [PubMed - indexed for MEDLINE]

5: Wilson GB, Paddock GV, Fudenberg HH. Related Articles

Bovine 'transfer factor': an oligoribonucleopeptide which initiates antigen-specific lymphocytes responsiveness.
Thymus. 1982;4(6):335-50.
PMID: 6191411 [PubMed - indexed for MEDLINE]

6: Wilson GB, Paddock GV, Fudenberg HH. Related Articles

Effects of dialyzable leukocyte extracts with transfer factor activity on leukocyte migration in vitro. V. Antigen-specific lymphocyte responsiveness can be initiated by two structurally distinct polyribonucleopeptides.
Thymus. 1981 Feb;2(4-5):257-6.
PMID: 6165106 [PubMed - indexed for MEDLINE]

7: Fudenberg HH, Wilson GB, Smith CL. Related Articles

Immunotherapy with dialyzable leukocyte extracts and studies of their antigen-specific (transfer factor) activity.

Proc Virchow Pirquet Med Soc. 1980 Dec;34:3-87. Review. No abstract available.
PMID: 6270691 [PubMed - indexed for MEDLINE]

☐8: Kyong CU, Wilson GB, Fudenberg HH, Goust JM, Richardson P, Echerd J. Related Articles
Chorioretinitis with a combined defect in T and B lymphocytes and granulocytes. A new syndrome successfully treated with dialyzable leukocyte extracts (transfer factor).
Am J Med. 1980 Jun;68(6):955-61.
PMID: 6992573 [PubMed - indexed for MEDLINE]

☐9: Wilson GB, Fudenberg HH, Jonsson HT Jr, Smith CL. Related Articles
Effects of dialyzable leukocyte extracts (DLE) with transfer factor activity on leukocyte migration in vitro. IV. Two distinct effects of DLE on leukocyte migration can be produced by prostaglandins.
Clin Immunol Immunopathol. 1980 May;16(1):90-102. No abstract available.
PMID: 7379353 [PubMed - indexed for MEDLINE]

☐10: Wilson GB, Newell RT, Burdash NM. Related Articles
Bovine dialyzable lymph node extracts have antigen-dependent and antigen-independent effects on human cell-mediated immunity in vitro.
Cell Immunol. 1979 Sep 15;47(1):1-18. No abstract available.
PMID: 315822 [PubMed - indexed for MEDLINE]

☐11: Wilson GB, Smith CL, Fudenberg HH. Related Articles
Effects of dialyzable leukocyte extracts (DLEs) with transfer factor activity on leukocyte migration in vitro. III. Characterization of the antigen-independent migration inhibition factor in DLEs as a neutrophil immobilizing factor.
J Allergy Clin Immunol. 1979 Jul;64(1):56-66.
PMID: 447952 [PubMed - indexed for MEDLINE]

☐12: Wilson GB, Fudenberg HH. Related Articles
Effects of dialyzable leukocyte extracts with transfer factor activity on leukocyte migration in vitro. II. Separation and partial characterization of the components in DLE producing antigen-dependent and antigen-independent effects.
J Lab Clin Med. 1979 May;93(5):819-37.
PMID: 429877 [PubMed - indexed for MEDLINE]

☐13: Wilson GB, Fudenberg HH, Horsmanheimo M. Related Articles
Effects of dialyzable leukocyte extracts with transfer factor activity on leukocyte migration in vitro. 1. Antigen-dependent inhibition and antigen-independent inhibition and enhancement of migration.
J Lab Clin Med. 1979 May;93(5):800-18.
PMID: 429876 [PubMed - indexed for MEDLINE]

☐14: Wilson GB, Fudenberg HH, Paddock GV. Related Articles
Detection of "dialyzable transfer factor" in vitro: structural and chemical characterization of the activity specific for tuberculin.
Ann N Y Acad Sci. 1979;332:579-90. No abstract available.
PMID: 294834 [PubMed - indexed for MEDLINE]

☐15: Wilson GB, Paddock GV, Fudenberg HH. Related Articles
The chemical nature of the antigen-specific moiety of transfer factor.

Trans Assoc Am Physicians. 1979;92:239-56. No abstract available.
PMID: 95068 [PubMed - indexed for MEDLINE]

☐**16:** Wilson GB, Fudenberg HH, Bahm VJ. Related Articles

Distinct components in dialyzable leukocyte extracts (DLE) have specific and nonspecific effects on cellular immunity as shown by leukocyte migration inhibition.
Trans Assoc Am Physicians. 1978;91:295-332. No abstract available.
PMID: 754397 [PubMed - indexed for MEDLINE]

☐**17:** Wilson GB, Welch TM, Knapp DR, Horsmanheimo A, Fudenberg HH. Related Articles

Characterization of Tx, an active subfraction of human dialyzable transfer factor. I. Identification of the major component in TFg, a precursor of Tx, as hypoxanthine.
Clin Immunol Immunopathol. 1977 Nov;8(3):551-68. No abstract available.
PMID: 912950 [PubMed - indexed for MEDLINE]

☐**18:** Wilson GB, Welch TM, Fudenberg HH. Related Articles

Tx: a component in human dialyzable transfer factor that induces cutaneous delayed hypersensitivity in guinea pigs.
Clin Immunol Immunopathol. 1977 Mar;7(2):187-202. No abstract available.
PMID: 862252 [PubMed - indexed for MEDLINE]

Display Summary Sort Save Text Clip Add Order

Show: 20 Items 1-18 of 18 One page.